BAGGIO, L. L. & DRUCKER, D. J. 2007. Biology of Incretins: GLP-1 and GIP. Gastroenterology, 132, 2131-2157.
BEN-SHLOMO, S., ZVIBEL, I., SHNELL, M., SHLOMAI, A., CHEPURKO, E., HALPERN, Z., BARZILAI, N., OREN, R. & FISHMAN, S. 2011. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. Journal of Hepatology, 54, 1214-1223.
DRUCKER, D. J. 2018. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 27, 740-756.
GROSS, D. N., WAN, M. & BIRNBAUM, M. J. 2009. The role of FOXO in the regulation of metabolism. Current Diabetes Reports, 9, 208-214.
GUPTA, N. A., MELLS, J., DUNHAM, R. M., GRAKOUI, A., HANDY, J., SAXENA, N. K. & ANANIA, F. A. 2010. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis <em>in vitro</em> by modulating elements of the insulin signaling pathway. Hepatology, 51, 1584-1592.
HOLST, J. J. 2007. The Physiology of Glucagon-like Peptide 1. Physiological Reviews, 87, 1409-1439.
J.DRUCKER, D. 2016. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metabolism, 24, 15-30.
LEE, Y. S., SHIN, S., SHIGIHARA, T., HAHM, E., LIU, M. J., HAN, J., YOON, J. W. & JUN, H. S. 2007. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes, 56, 1671-9.
LIU, M., LIU, H., XIE, J., XU, Q. & LIU, J. 2017. Antiobesity effects of zeaxanthin on 3T3-L1 preadipocyte and high fat induced obese mice. Food & Function, 8, 3327.
MUSSMANN, R., GEESE, M., HARDER, F., KEGEL, S., ANDAG, U., LOMOW, A., BURK, U., ONICHTCHOUK, D., DOHRMANN, C. & AUSTEN, M. 2007. Inhibition of GSK3 Promotes Replication and Survival of Pancreatic Beta Cells. Journal of Biological Chemistry, 282, 12030-12037.
NAIM, P., MULVIHILL, E. E., CHRISTINE, L., BERNARDO, Y., CAMPBELL, J. E., BROWN, T. J., CATHERINE, S., DIANNE, H., CAO, X. & BAGGIO, L. L. 2013. GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice. Endocrinology, 1.
NICKAVAR, B. & AMIN, G. 2004. Effects of Glucagon-like Peptide 1 on the Hepatic Glucose Metabolism. Hormone & Metabolic Research, 36, 837-841.
POSTIC, C. & GIRARD, J. 2008. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. Journal of Clinical Investigation, 118, 829-838.
PYKE, C., HELLER, R. S. & KIRK, R. K. 2014. GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody. Endocrinology, 155, 1280-1290.
SAVAGE, D. B., PETERSEN, K. F. & SHULMAN, G. I. 2007. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev, 87, 507-20.
STANHOPE, K. L., SCHWARZ, J. M., KEIM, N. L., GRIFFEN, S. C., BREMER, A. A., GRAHAM, J. L., HATCHER, B., COX, C. L., DYACHENKO, A. & ZHANG, W. 2009. Consuming fructose-sweetened , not glucose- sweetened , beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight / obese humans. Journal of Clinical Investigation, 119, 1322-1334.
STEINBERG, G. R. & KEMP, B. E. 2009. AMPK in Health and Disease. Physiol Rev, 89, 1025-1078.
SVEGLIATI-BARONI, G., SACCOMANNO, S. & RYCHLICKI, C. 2011a. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver International Official Journal of the International Association for the Study of the Liver, 31, 1285-1297.
SVEGLIATI-BARONI, G., SACCOMANNO, S., RYCHLICKI, C., AGOSTINELLI, L., DE MINICIS, S., CANDELARESI, C., FARACI, G., PACETTI, D., VIVARELLI, M., NICOLINI, D., GARELLI, P., CASINI, A., MANCO, M., MINGRONE, G., RISALITI, A., FREGA, G. N., BENEDETTI, A. & GASTALDELLI, A. 2011b. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver International, 31, 1285-1297.
TUSHUIZEN, M. E., BUNCK, M. C., POUWELS, P. J., VAN WAESBERGHE, J. H., DIAMANT, M. & HEINE, R. J. 2006. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int, 26, 1015-1017.
VIOLLET, B., FORETZ, M., GUIGAS, B., HORMAN, S., DENTIN, R., BERTRAND, L., HUE, L. & ANDREELLI, F. 2006. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. The Journal of Physiology, 574, 41-53.
WHO. 2016. Global report on diabetes.
ZHAO, L., GUO, X., WANG, O., ZHANG, H., WANG, Y., ZHOU, F., LIU, J. & JI, B. 2016. Fructose and glucose combined with free fatty acids induce metabolic disorders in HepG2 cell: A new model to study the impacts of high-fructose/sucrose and high-fat diets in vitro. Molecular Nutrition & Food Research, 60, 909-921.
ZHOU, D., CHEN, Y.-W., ZHAO, Z.-H., YANG, R.-X. & XIN, F.-Z. 2018a. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Experimental & Molecular Medicine.
ZHOU, D., CHEN, Y., ZHAO, Z., YANG, R., XIN, F., LIU, X., PAN, Q., ZHOU, H. & FAN, J. 2018b. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Experimental and Molecular Medicine, 50, 157.